View Item 

Show simple item record

The impact of direct‐acting antiviral agents on liver and kidney transplant costs and outcomes
dc.contributor.authorAxelrod, D. A.
dc.contributor.authorSchnitzler, M. A.
dc.contributor.authorAlhamad, T.
dc.contributor.authorGordon, F.
dc.contributor.authorBloom, R. D.
dc.contributor.authorHess, G. P.
dc.contributor.authorXiao, H.
dc.contributor.authorNazzal, M.
dc.contributor.authorSegev, D. L.
dc.contributor.authorDharnidharka, V. R.
dc.contributor.authorNaik, A. S.
dc.contributor.authorLam, N. N.
dc.contributor.authorOuseph, R.
dc.contributor.authorKasiske, B. L.
dc.contributor.authorDurand, C. M.
dc.contributor.authorLentine, K. L.
dc.date.accessioned2018-11-20T15:31:52Z
dc.date.available2019-12-02T14:55:09Zen
dc.date.issued2018-10
dc.identifier.citationAxelrod, D. A.; Schnitzler, M. A.; Alhamad, T.; Gordon, F.; Bloom, R. D.; Hess, G. P.; Xiao, H.; Nazzal, M.; Segev, D. L.; Dharnidharka, V. R.; Naik, A. S.; Lam, N. N.; Ouseph, R.; Kasiske, B. L.; Durand, C. M.; Lentine, K. L. (2018). "The impact of direct‐acting antiviral agents on liver and kidney transplant costs and outcomes." American Journal of Transplantation 18(10): 2473-2482.
dc.identifier.issn1600-6135
dc.identifier.issn1600-6143
dc.identifier.urihttps://hdl.handle.net/2027.42/146297
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhealth services and outcomes research
dc.subject.otherkidney (allograft) function/dysfunction
dc.subject.otherkidney transplantation/nephrology
dc.subject.otherliver allograft function/dysfunction
dc.subject.otherliver transplantation/hepatology
dc.subject.otherpatient survival
dc.subject.otherinfection and infectious agents – viral: hepatitis C
dc.subject.otherclinical research/practice
dc.subject.othereconomics
dc.titleThe impact of direct‐acting antiviral agents on liver and kidney transplant costs and outcomes
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146297/1/ajt14895_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146297/2/ajt14895.pdf
dc.identifier.doi10.1111/ajt.14895
dc.identifier.sourceAmerican Journal of Transplantation
dc.identifier.citedreferenceKabiri M, Chhatwal J, Donohue JM, et al. Long‐term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthc (Amst). 2017; 5 ( 3 ): 105 ‐ 111.
dc.identifier.citedreferenceCharlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015; 149 ( 3 ): 649 ‐ 659.
dc.identifier.citedreferenceAlqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015; 62 ( 1 ): 25 ‐ 30.
dc.identifier.citedreferenceReddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015; 62 ( 1 ): 79 ‐ 86.
dc.identifier.citedreferenceCurry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373 ( 27 ): 2618 ‐ 2628.
dc.identifier.citedreferenceBackus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct‐acting antiviral treatment on mortality in patients with advanced liver disease [published online ahead of print July 27, 2017]. Hepatology. https://doi.org/10.1002/hep.29408
dc.identifier.citedreferenceSpengler U. Direct antiviral agents (DAAs) ‐ A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018; 183: 118 ‐ 126.
dc.identifier.citedreferenceEverson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013; 57 ( 5 ): 1752 ‐ 1762.
dc.identifier.citedreferenceMucke MM, Mucke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver Int. 2018; 38 ( suppl 1 ): 14 ‐ 20.
dc.identifier.citedreferenceMucke MM, Mucke VT, Lange CM, Zeuzem S. Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. Liver Int. 2017; 37 ( suppl 1 ): 19 ‐ 25.
dc.identifier.citedreferenceCoilly A, Roche B, Duclos‐Vallee JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol. 2016; 1 ( 2 ): 165 ‐ 172.
dc.identifier.citedreferenceFelmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis. 2016; 16 ( 6 ): 735 ‐ 745.
dc.identifier.citedreferenceJadoul M, Martin P. Hepatitis C treatment in chronic kidney disease patients: the kidney disease improving global outcomes perspective. Blood Purif. 2017; 43 ( 1–3 ): 206 ‐ 209.
dc.identifier.citedreferencePatel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010; 56 ( 2 ): 371 ‐ 378.
dc.identifier.citedreferenceMendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories. J Viral Hepatitis. 2017; 24 ( 6 ): 442 ‐ 453.
dc.identifier.citedreferenceBruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4‐5 chronic kidney disease: clinical, virological, and health‐related quality‐of‐life outcomes from a phase 3, multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Gastroenterol Hepatol. 2017; 2 ( 8 ): 585 ‐ 594.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Jacobson IM, et al. Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naive chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 2018; 47 ( 2 ): 259 ‐ 267.
dc.identifier.citedreferenceSawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015; 99 ( 12 ): 2458 ‐ 2466.
dc.identifier.citedreferenceColombo M, Aghemo A, Liu H, et al. Treatment with Ledipasvir‐Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017; 166 ( 2 ): 109 ‐ 117.
dc.identifier.citedreferenceBarua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015; 163 ( 3 ): 215 ‐ 223.
dc.identifier.citedreferenceCampbell CA, Canary L, Smith N, Teshale E, Ryerson AB, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs ‐ United States, 2015‐2016. MMWR Morb Mortal Wkly Rep. 2017; 66 ( 18 ): 465 ‐ 469.
dc.identifier.citedreferenceCheung MCM, Walker AJ, Hudson BE, et al. Outcomes after successful direct‐acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 65 ( 4 ): 741 ‐ 747.
dc.identifier.citedreferenceSmith‐Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015; 15: 19.
dc.identifier.citedreferenceSamur S, Kues B, Ayer T, et al. Cost effectiveness of pre‐ vs post‐liver transplant hepatitis C treatment with direct‐acting antivirals. Clin Gastroenterol Hepatol. 2018; 16 ( 1 ): 115 ‐ 122 e110.
dc.identifier.citedreferenceChhatwal J, Samur S, Bethea ED, et al. Transplanting HCV‐positive livers into HCV‐negative patients with preemptive antiviral treatment: a modeling study [published online ahead of print December 9, 2017]. Hepatology. https://doi.org/10.1002/hep.29723.
dc.identifier.citedreferenceBethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis Hepatology. 2018; 67: 837 ‐ 846.
dc.identifier.citedreferenceAxelrod DA, Naik AS, Schnitzler MA, et al. National variation in use of immunosuppression for kidney transplantation: a call for evidence‐based regimen selection. Am J Transplant. 2016; 16 ( 8 ): 2453 ‐ 2462.
dc.identifier.citedreferenceGadiparthi C, Cholankeril G, Perumpail BJ, et al. Use of direct‐acting antiviral agents in hepatitis C virus‐infected liver transplant candidates. World J Gastroenterol. 2018; 24 ( 3 ): 315 ‐ 322.
dc.identifier.citedreferenceCholankeril G, Joseph‐Talreja M, Perumpail BJ, et al. Timing of hepatitis C virus treatment in liver transplant candidates in the era of direct‐acting antiviral agents. J Clin Transl Hepatol. 2017; 5 ( 4 ): 363 ‐ 367.
dc.identifier.citedreferenceAhmed A, Gonzalez SA, Cholankeril G, et al. Treatment of patients waitlisted for liver transplant with all‐oral direct‐acting antivirals is a cost‐effective treatment strategy in the United States. Hepatology. 2017; 66 ( 1 ): 46 ‐ 56.
dc.identifier.citedreferenceJadoul M, Martin P. Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation? Semin Dial. 2017; 30 ( 5 ): 395 ‐ 397.
dc.identifier.citedreferenceShelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis. 2018; 20: e12829.
dc.identifier.citedreferenceHe T, Lopez‐Olivo MA, Hur C, Chhatwal J. Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6. Aliment Pharmacol Ther. 2017; 46 ( 8 ): 711 ‐ 721.
dc.identifier.citedreferenceAggarwal R, Chen Q, Goel A, et al. Cost‐effectiveness of hepatitis C treatment using generic direct‐acting antivirals available in India. PLoS ONE. 2017; 12 ( 5 ): e0176503.
dc.identifier.citedreferenceSawinski D, Wyatt CM, Locke JE. Expanding the use of hepatitis C‐viremic kidney donors. Kidney Int. 2017; 92 ( 5 ): 1031 ‐ 1033.
dc.identifier.citedreferenceBelli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017; 67 ( 3 ): 585 ‐ 602.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt14895_am.pdf
Size:
776.2KB
Format:
PDF
View/Open
Name:
ajt14895.pdf
Size:
471.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.